We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Humacyte, Inc. (HUMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Humacyte, Inc. is a member of our Medical group, which includes 933 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Humacyte, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HUMA's full-year earnings has moved 15.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, HUMA has gained about 12.4% so far this year. At the same time, Medical stocks have gained an average of 7.6%. This shows that Humacyte, Inc. is outperforming its peers so far this year.
Acrivon Therapeutics, Inc. (ACRV - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 24.9%.
The consensus estimate for Acrivon Therapeutics, Inc.'s current year EPS has increased 13.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Humacyte, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 454 individual stocks and currently sits at #106 in the Zacks Industry Rank. This group has gained an average of 18.6% so far this year, so HUMA is slightly underperforming its industry in this area.
Acrivon Therapeutics, Inc., however, belongs to the Medical - Drugs industry. Currently, this 141-stock industry is ranked #90. The industry has moved +3.1% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Humacyte, Inc. and Acrivon Therapeutics, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Humacyte, Inc. (HUMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Humacyte, Inc. is a member of our Medical group, which includes 933 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Humacyte, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HUMA's full-year earnings has moved 15.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, HUMA has gained about 12.4% so far this year. At the same time, Medical stocks have gained an average of 7.6%. This shows that Humacyte, Inc. is outperforming its peers so far this year.
Acrivon Therapeutics, Inc. (ACRV - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 24.9%.
The consensus estimate for Acrivon Therapeutics, Inc.'s current year EPS has increased 13.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Humacyte, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 454 individual stocks and currently sits at #106 in the Zacks Industry Rank. This group has gained an average of 18.6% so far this year, so HUMA is slightly underperforming its industry in this area.
Acrivon Therapeutics, Inc., however, belongs to the Medical - Drugs industry. Currently, this 141-stock industry is ranked #90. The industry has moved +3.1% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Humacyte, Inc. and Acrivon Therapeutics, Inc. as they could maintain their solid performance.